ACINETOBACTER CALCOACETICUS- ACINETOBACTER BAUMANNII (ABC) AND NEW SPECIES

Yıl 2020, Cilt: 21 Sayı: 2, 211 - 216, 11.05.2020

Berrin Esen , Ayşegül Gözalan

https://doi.org/10.18229/kocatepetip.545268

Cited By: 1

Öz

The Acinetobacter genus had 12 genomic species. In the last 30 years based on DNA-DNA hybridization the taxonomic differences has been reported. Currently 49 species are recognized. The biochemically indistinguishable strains, A. baumannii (genomik species 2), Acinetobacter nosocomialis (genomik species 13TU), Acinetobacter pittii (genomik species 3) and Acinetobacter calcoaceticus (genomik species 1) are the clinical important species in the A.calcoaceticus- A.baumannii complex (ABC). Two nowel pathogenic species, Acinetobacter seifertii and Acinetobacter djikshoorniae has been included to A. calcoaceticus- A.baumannii complex by DNA-DNA hybridizaition method, rpoB gene sequence analysis and multilocus sequence typing (MLST) methods. Draft genome sequence of a pathogenic strain JVAP01T, model strain of A. djikshoorniae, which a conjugative plasmid with blaNDM-1 gene has been reported. RNA polimerase β-subunit (rpoB)gene, DNA gyrase B (gyrB) gene sequence analysıs and /or multilocus sequence analysis (MLSA) are known as gold standard molecular methods for the idenitfication at species level. Others are amplified ribosomal DNA restriction analysis (ARDRA), Fourier transform infrared spectroscopy (FTIR) and Matriks assisted lazer desorption ionization time of flight mass spectrometry (MALDI-TOF MS). There is critical importance in keeping the development of antimicrobial resistance of Acinetobacter species at lowest levels such as using relaible laboratory methods, continous infection control measures and rationale antibiotic strategies.

Anahtar Kelimeler

A. calcoaceticus- A. baumannii complex, Acinetobacter seifertii, Acinetobacter djikshoorniae

ACINETOBACTER CALCOACETICUS- ACINETOBACTER BAUMANNII COMPLEX (ABC) VE YENİ TÜRLERİ

Öz

Acinetobacter cinsi’nin sınıflandırılmasında 12 farklı genomik tür bulunduğu gösterilmiş, taksonomisinde son 30 yılda DNA-temelli metotların yaygın kullanımı sayesinde değişiklikler kaydedilmiştir. Bugün için Acinetobacter cinsi içerisinde 49 tür bulunmaktadır. A. calcoaceticus- A.baumannii complex içinde (ABC) klinik olarak önemli türler olan A. baumannii (genomik tür 2), Acinetobacter nosocomialis (genomik tür 13TU), Acinetobacter pittii (genomik tür 3) ve Acinetobacter calcoaceticus (genomik tür 1) türleri biyokimyasal olarak ayırd edilemezler. DNA-DNA hibridizasyon, rpoB gen sekans analizi ve multilocus sequence typing (MLST) ile A. calcoaceticus- A. baumannii complex’e son yıllarda iki yeni patojenik tür olan Acinetobacter seifertii ve Acinetobacter djikshoorniae eklenmiştir. Ayrıca non-A.baumannii türleri arasında plazmide lokalize blaNDM-1 geni taşıyan ve A. djikshoorniae’nın model suşu olan JVAP01T suşunun taslak genom dizilimi de yayınlanmıştır. Bugün için; Acinetobacter cinsinin tür düzeyinde ayrımı için; RNA polimeraz β-subunit (rpoB) geni, DNA giraz B (gyrB) geni sekans analizi ve/veya multilocus sequence analysis (MLSA) altın standard moleküler metotlar olarak kabul edilmektedir. Diğer yöntemler; amplified ribosomal DNA restriction analysis (ARDRA), Fourier transform infrared spectroscopy (FTIR) , ve Matriks assisted lazer desorption ionization time of flight mass spectrometry (MALDI-TOF MS)’dur. Acinetobacter türlerine karşı antimikrobiyal direnç gelişimini önlemek için izolatların tür düzeyinde güvenilir yöntemler kullanılarak tanımlanmaları, uygun antibiyotiklerin kullanılması ve kesintisiz enfeksiyon kontrol önlemlerinin uygulanması önemlidir.

Anahtar Kelimeler

A.calcoaceticus- A.baumannii complex, Acinetobacter seifertii, Acinetobacter djikshoorniae

Kaynakça

• 1) Lynch JP 3rd, Zhanel GG, Clark NM. Infections Due to Acinetobacter baumannii in the ICU: Treatment Options. Semin Respir Crit Care Med. 2017; Jun;38(3):311-325. doi: 10.1055/s-0037-1599225.
• 2) Nowak, P., Paluchowska P. Acinetobacter baumannii: biology and drug resistance - role of carbapenemases. Folia Histochem Cytobiol. 2016;54(2), 61-74.
• 3) Cisneros, J.M., Rodríguez-Baño J., Fernández-Cuenca F. Et al. Spanish Group for Nosocomial Infection (GEIH) for the Spanish Society of Infectious Diseases and Clinical Microbiology(SEIMC). Risk factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. Clin Microbiol Infect. 2005; 11(11), 874-9.
• 4) Sheng, W.H., Liao C.H., Lauderdale T.L., Ko W.C., et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. 2010;Int J Infect Dis, 14(9), e764-9.
• 5) Ng, T.M., Teng C.B., Lye D.C., et al. A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia. Infect. Control Hosp. 2014;Epidemiol, 35(1), 49-55.
• 6) Aydın, M., Ergönül Ö., Azap A. Et al. Turkish Society of Clinical Microbiology and Infectious Diseases, Healthcare-related Infections Study Group, Turkey. Rapid emergence of colistin resistance and its impact on fatality among healthcare-associated infections. 2018 ; J Hosp Infect, 98(3), 260-263.
• 7) Cai, Y., Chai D., Wang R., Liang B., Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother, 2012; 67(7), 1607-15.
• 8) Doi, Y., Murray G.L., Peleg A.Y. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med, 2015; 36, 85–98.
• 9) Go, E.S., Urban C., Burns J. Et al. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet, 1994;12, 344(8933):1329-32.
• 10) Lin, M.F., Lan C.Y. Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases, 2014; 16;2(12), 787-814.
• 11) Lee, C.R., Lee J.H., Park M. Et al. Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options. Front Cell Infect Microbiol. 2017; 13, 7:55.
• 12)Lob, S.H., Hoban D.J., Sahm D.F., Badal E. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents, 2016; 47(4), 317-23.
• 13) Versalovic, J., Carroll, K.C., Funke, G., Jorgensen, J.H., Landry, M.L., Warnock(Editörler). Manual of Clinical Microbiology. In: Vaneechoutte, M., Dijkshoorn, L., Nemec, A., Kampfer, P., Wauters, G. Acinetobacter, Chryseobacterium, Moraxella, an other Nonfermentative Gram-Negative rods. Washington DC: ASM press, D.W. 2011.
• 14) Bartual, S.G., Seifert H., Hippler C. Et al. F. Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii. J Clin Microbiol, 2005;43(9), 4382-90. Erratum in: J Clin Microbiol. 2007;. Jun;45(6):2101.
• 15) Bouvet, P.J., Jeanjean S. Delineation of new proteolytic genomic species in the genus Acinetobacter. Res Microbiol, 1989 ; 140(4-5), 291-9.
• 16) Tjernberg, I., Ursing J. Clinical strains of Acinetobacter classified by DNA-DNA hybridization. APMIS, 1989; 97(7), 595-605.
• 17) Cosgaya, C., Marí-Almirall M., Van Assche A. Et al. Acinetobacter dijkshoorniae sp. nov., a member of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex mainly recovered from clinical samples in different countries. Int J Syst Evol Microbiol, 2016; 66(10), 4105-4111.
• 18) Marí-Almirall, M., Cosgaya C., Higgins P.G. et al. MALDI-TOF/MS identification of species from the Acinetobacter baumannii (Ab) group revisited: inclusion of the novel A. seifertii and A. dijkshoorniae species. Clin Microbiol Infect, 2017; 23(3), 210.e1-210.e9.
• 19) Gerner-Smidt, P., Tjernberg I., Ursing J. Reliability of phenotypic tests for identification of Acinetobacter species. 1991; J Clin Microbiol, 29(2), 277-82.
• 20) Wisplinghoff H, Paulus T, Lugenheim M. Et al. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J Infect. 2012; Mar;64(3):282-90.
• 21) Wang X, Chen T, Yu R, Lü X, Zong Z. Acinetobacter pittii and Acinetobacter nosocomialis among clinical isolates of the Acinetobacter calcoaceticus-baumanniicomplex in Sichuan, China. Diagn Microbiol Infect Dis. 2013 Jul;76(3):392-5.
• 22) Karah N, Haldorsen B, Hegstad K et al; Norwegian Study Group of Acinetobacter. Species identification and molecular characterization of Acinetobacter spp. blood culture isolates from Norway. J Antimicrob Chemother. 2011 Apr;66(4):738-44.
• 23) Nemec, A., Krizova L., Maixnerova M. Et al. Acinetobacter seifertii sp. nov., a member of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolated from human clinical specimens. Int J Syst Evol Microbiol. 2015; 65(Pt 3), 934-42.
• 24) Gerner-Smidt, P., Tjernberg I. Acinetobacter in Denmark: II. Molecular studies of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex. APMIS. 1993 ; 101(11), 826-32.
• 25) Nemec, A., Krizova L., Maixnerova M. Et al. Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU). Res Microbiol, 2011; 162(4), 393-404.
• 26) Espinal, P., Mosqueda N., Telli M. Identification of NDM-1 in a Putatively Novel Acinetobacter Species ("NB14") Closely Related to Acinetobacter pittii. Antimicrob Agents Chemother. 2015 ; 59(10), 6657-60.
• 27) Fernández-Orth D, Cosgaya C, Telli M et al. Draft Genome Sequence of JVAP01T, the Type Strain of the Novel Species Acinetobacter dijkshoorniae. Genome Announc. 2017 Jan 12;5(2). pii: e01480-16.doi: 10.1128/genomeA.01480-16. PubMed PMID: 28082506; PubMed Central PMCID:PMC5256222.)
• 28) World Health Organization. “Global priority list of antibiotic-resist¬ant bacteria to guide research, discovery, and development of new antibiotics. Geneva: WHO; 2017” http://www.who. int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_ NM_WHO.pdf. Son erişim tarihi: 25 07 2018.
• 29) Boo, T.W., Walsh F., Crowley B.. “Molecular characterization of carbapenem-resistant Acinetobacter species in an Irish university hospital: predominance of Acinetobacter genomic species 3. J Med Microbiol, 2009; 58(Pt 2), 209-16.
• 30) Lee, H.Y., Chen C.L., Wu S.R. Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients. Crit Care Med, 2014; 42(5), 1081-8.
• 31) Chusri, S., Chongsuvivatwong V., Rivera J.I. et al. Clinical outcomes of hospital-acquired infection with Acinetobacter nosocomialis and Acinetobacter pittii. Antimicrob Agents Chemother, 2014; 58(7), 4172-9.
• 32) Wang, J., Ruan Z., Feng Y. Et al. Species distribution of clinical Acinetobacter isolates revealed by different identification techniques. ; PLoS One, 13;9(8), e104882.
• 33) La Scola, B., Gundi V.A., Khamis A. Et al. Sequencing of the rpoB gene and flanking spacers for molecular identification of Acinetobacter species. J Clin Microbiol, 2006 ; 44(3), 827-32.
• 34) Higgins, P.G., Lehmann M., Wisplinghoff H. Et al. gyrB multiplex PCR to differentiate between Acinetobacter calcoaceticus and Acinetobacter genomic species 3. J Clin Microbiol. 2010; 48(12), 4592-4.(b)
• 35) Turton, J.F., Woodford N., Glover J et al. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol, 2006 ; 44(8), 2974-6.
• 36) Lee, Y.T., Kuo S.C., Chiang M.C. et al. Emergence of carbapenem-resistant non-baumannii species of Acinetobacter harboring a blaOXA-51-like gene that is intrinsic to A. baumannii. Antimicrob Agents Chemother. 2012; 56(2), 1124-7.
• 37) Wang, J., Ruan Z., Feng Y. Et al. Species distribution of clinical Acinetobacter isolates revealed by different identification techniques. PLoS One, 2014;13;9(8), e104882.
• 38) Vaneechoutte, M., Dijkshoorn L., Tjernberg I. Et al. Identification of Acinetobacter genomic species by amplified ribosomal DNA restriction analysis. J Clin Microbiol, 1995 ; 33(1), 11-5.39) Dijkshoorn, L., Van Harsselaar B., Tjernberg I. Evaluation of amplified ribosomal DNA restriction analysis for identification of Acinetobacter genomic species. Syst Appl Microbiol, 1998; 21(1), 33-9.
• 40) Sousa C, Silva L, Grosso F, et al. Discrimination of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex species by Fourier transform infrared spectroscopy. Eur J Clin Microbiol Infect Dis 2014; 33:1345–1353.
• 41) Šedo O, Nemec A, Křížová L, et al. Improvement of MALDI-TOF MS profiling for the differentiation of species within the Acinetobacter calcoaceticus-Acinetobacter baumannii complex. Syst Appl Microbiol. 2013; 36:572–578.
• 42) Hsueh P-R, Kuo L-C, Chang T-C, et al. Evaluation of the Bruker Biotyper matrix-assisted laser desorption ionization-time of flight mass spectrometry system for identification of blood isolates of Acinetobacter species. J Clin Microbiol 2014; 52:3095–3100.
• 43) Alvarez-Buylla A, Culebras E, Picazo JJ. Identification of Acinetobacter species: is Bruker biotyper MALDI-TOF mass spectrometry a good alternative to molecular techniques? Infect Genet Evol. 2012;12:345–349.
• 44) Dijkshoorn, L., Aucken H., Gerner-Smidt P., Janssen P., Kaufmann M.E., Garaizar J., Ursing J., Pitt TL. “Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods. J Clin Microbiol, 1996; 34(6), 1519-25.
• 45) van Dessel, H., Dijkshoorn L., van der Reijden T. Et al. Identification of a new geographically widespread multiresistant Acinetobacter baumannii clone from European hospitals. Res Microbiol, 2004; 155(2), 105-12.
• 46) Dijkshoorn, L., Nemec A., Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol, 2007; 5(12), 939-51.47) Metan, G., Sariguzel F., Sumerkan B. Et al. Clonal diversity and high prevalence of OXA-58 among Acinetobacter baumannii isolates from blood cultures in a tertiary care centre in Turkey.”, Infect Genet Evol. 2013 ;14, 92-7. Erratum in:Infect Genet Evol, 2013; 16, 447-8.
• 48) Castanheira, M., Costello S.E., Woosley L.N. et al. Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel β-lactamases, GES-22 and VIM-35. Antimicrob Agents Chemother. 2014; 58(12), 7358-66.
• 49) Ahmed, S.S., Alp E., Ulu-Kilic A. Et al. Spread of carbapenem-resistant international clones of Acinetobacter baumannii in Turkey and Azerbaijan: a collaborative study. Eur J Clin Microbiol Infect Dis, 2016 ; 35(9), 1463-8.
• 50) Wisplinghoff H, Paulus T, Lugenheim M et al. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J Infect. 2012 Mar; 64(3):282-90. doi: 10.1016/j.jinf.2011.12.008. Epub 2011 Dec 20. PubMed PMID: 22209744.
• 51) Zander E, Fernández-González A, Schleicher X et al. Worldwide dissemination of acquired carbapenem-hydrolysing class D β-lactamases in Acinetobacter spp. other than Acinetobacter baumannii. Int J Antimicrob Agents. 2014 Apr; 43(4):375-7. doi: 10.1016/j.ijantimicag.2014.01.012. Epub 2014 Feb 12. PubMed PMID: 24612983.)